In vivo assay to determine cancer treatment effectiveness

• US 5,676,924 A
• Filed: 12/17/1993
• Issued: 10/14/1997
• Est. Priority Date: 10/02/1991
• Status: Expired due to Term

• Current Assignee: Rhode Island Hospital
• Original Assignee: Rhode Island Hospital
• Inventors: Bagtas, Justiniano F., Forman, Edwin N., Lipsky, Milton H.
• Primary Examiner(s): Crouch, Deborah
• Application Number:
  US08/169,312
• Time in Patent Office: 1,397 Days
• Field of Search: 424/9, 424/93.7, 424/9.2, 424/9.1, 435/240, 435/242
• US Class Current: 424/9.2
• CPC Class Codes: A61K 49/0008 Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure

Abstract

A method of determining the effectiveness of a cancer treatment by sealing tumor cells in segments of semipermeable membrane hollow fibers, implanting the sealed fiber segments in a mammal, treating the mammal with a cancer treatment, and evaluating the effect of the cancer treatment on the cells in the hollow fiber segments.

Claims

1. A method of determining the effectiveness of a cancer treatment comprising,

providing elongated segments of semipermeable membrane hollow fibers having a pore size effective to permit passage of nutrients, and wherein said pore size excludes components of a mammal'"'"'s immune system which induce tissue rejection,

inserting tumor cells into said hollow fibers,

sealing the ends of said hollow fibers,

implanting said sealed hollow fibers intraperitoneally or subcutaneously into a non-human mammal,

administering the cancer treatment, and

monitoring the effectiveness of said treatment on the cells in said implanted hollow fibers.

2. The method of claim 1, wherein said mammal is immunocompetent.

3. The method of claim 2, wherein said mammal is a rat.

4. The method of claim 1, wherein said tumor cells are leukemic cells.

5. The method of claim 1, wherein said tumor cells are from a tumor of a patient.

6. The method of claim 5, wherein said cells are in suspension.

7. The method of claim 5, wherein said tumor cells are a tissue explant.

8. The method of claim 6, wherein said monitoring is the counting of viable cells in said fibers.

9. The method of claim 1, wherein said monitoring is a morphological examination of cells in said fibers.

10. The method of claim 1, wherein said implanting is intraperitoneally.

11. The method of claim 10, wherein said cancer therapy is a chemotherapeutic drug.

12. The method of claim 11, wherein said mammal is a rat.

13. The method of claim 1, wherein said implanting is subcutaneously.

14. The method of claim 13, wherein said cancer therapy is a chemotherapeutic drug.

15. The method of claim 14, wherein said mammal is a rat.

16. The method of claim 1, wherein said cancer treatment is a chemotherapeutic drug.

17. The method of claim 16, wherein said sealed fibers are implanted into a plurality of said mammals, and different chemotherapeutic drugs are administered to different of said plurality of mammals, and said monitoring is a comparison of results obtained from said different chemotherapeutic drugs.

18. The method of claim 1, wherein said cancer treatment is radiation therapy.

19. The method of claim 1, wherein different tumor cells are inserted into separate hollow fibers, and wherein said hollow fibers are sealed, implanted into said mammal, and the effectiveness of a cancer treatment on said different tumor cells is monitored.

20. The method of claim 1, wherein said fibers are polysulfone fibers.

21. The method of claim 20, wherein said fibers have pores with a molecular weight cutoff of 30,000 to 50,000 Daltons.

22. The method of claim 21, wherein said fibers have pores with a molecular weight cutoff of 30,000 Daltons.

23. The method of claim 1, wherein said pore size permits entry of immunotoxins.